De novo somatic BRCA1/2 mutations in breast cancer are considered to be rare: the prevalence of somatic BRCA1 gene mutations in primary tumors is only 1.55%, and that of somatic BRCA2 gene mutations is 1.68%42. This evidence concerns the gene BRCA1 and breast cancer.